Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology Brothers
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe

Your AI-Trained Oncology Knowledge Connection!

scout
Advertisement

(S005) Comparison of Legal Needs of a Group of Patients With Cancer: Economic and Geographic Factors

April 15, 2016
Publication
Article
OncologyOncology Vol 30 No 4_Suppl_1
Volume 30
Issue 4_Suppl_1
Conference|Annual Meeting of the American Radium Society (ARS)

Differences in the legal needs of economically and geographically diverse patients with cancer suggest that those needs are not determined solely by disease state but that they also correspond with geographic and economic characteristics.

Serguei A. Castaneda, MD, Tomas Bednar, JD, MA, Roderick Price, MS, Lydia Komarnicky-Kocher, MD; Department of Radiation Oncology, Cancer Center, Hahnemann University Hospital and Drexel University College of Medicine

BACKGROUND: Medical-legal partnerships (MLPs) identify and serve the legal needs of vulnerable patient populations. The specific legal needs of patients with cancer in urban hospitals are not completely characterized.

OBJECTIVE: To identify the legal needs of a group of patients from our cancer center, and the relationship between these needs and geography and income.

METHODS: We collected de-identified data on legal needs and demographic variables in 94 patients. We stratified patients into three groups, according to their income: (1) above the national average (> $53,046), (2) below the national average but above Medicaid eligibility for a family of three ($27,310–$53,046), and (3) below the line of Medicaid eligibility (< $27,310). We then compared the legal needs of these three subgroups with those of the total patient population.

RESULTS: Fifty-four percent of patients from the poorest zip codes showed a primary interest in income management and public benefits compared with 37% of the total population, whereas 47% of those from the most affluent areas had the strongest interest in advanced planning documents compared with 29% of the total population. In contrast, those from the middle-income group had a seemingly even distribution of needs compared with the total population. Needs related to consumer/employment (24%) and Medicaid/Medicare (22%) were distributed somewhat uniformly across the three subgroups. Furthermore, patients from the affluent zip codes identified needs in only five out of eight categories, leaving out housing, utilities, and miscellaneous, whereas the other two groups identified issues in nearly all of the categories.

CONCLUSIONS: Differences in the legal needs of economically and geographically diverse patients with cancer suggest that those needs are not determined solely by disease state but that they also correspond with geographic and economic characteristics. MLPs could help to anticipate and serve the specific legal needs of patients in urban cancer centers and possibly even patients with cancer in general. 

Proceedings of the 98th Annual Meeting of the American Radium Society - americanradiumsociety.org

Articles in this issue

(S002) A 15-Year Review of Radiation Therapy for Keloids at Two Institutions
(S003) Single-Fraction Radiation Therapy for the Treatment of Multiple Myeloma Bony Metastases Provides Pain Control and Decreases Time to Chemotherapy
(S001) Prognostic Value of Pretreatment Serum Inflammatory Markers in Patients Receiving Radiation Therapy for Oropharyngeal Cancer
(S004) Trend in Second Malignancy Risk for Head and Neck Cancer With Increased Utilization of IMRT: Analysis of SEER Database
(S005) Comparison of Legal Needs of a Group of Patients With Cancer: Economic and Geographic Factors
(S006) Mission Improvement: Lessons From Initiating a Resident-Led Quality Improvement Project on Smoking Cessation at a County Hospital
(S007) Results of a Phase II Trial Using Cetuximab Plus Docetaxel With Low-Dose Fractionated Radiation for Recurrent Unresectable Locally Advanced Head and Neck Carcinoma
(S008) The Effect of Simulation and Treatment Delays for Patients With Oropharyngeal Cancer Receiving Definitive Radiation Therapy in the Era of Risk Stratification Using Smoking and Human Papilloma Virus Status
(S009) Intensity-Modulated Radiation Therapy With Stereotactic Body Radiation Therapy Boost for Unfavorable Prostate Cancer: A Report on Three-Year Toxicity
(S011) Comparative Study Between Ileal Conduit and Indiana Pouch After Cystectomy for Patients With Carcinoma of Urinary Bladder
(S010) Computed Tomography–Assessed Measures of Bone Mineral Density and Muscle Mass as Predictors of Survival in Men With Prostate Cancer
(S012) Quantitative Imaging to Evaluate the Malignant Potential of Pancreatic Cysts
(S013) Spine Stereotactic Radiosurgery With Concurrent Tyrosine Kinase Inhibitors for Metastatic Renal Cell Carcinoma
(S014) The Impact of Radiation Therapy on Survival in Surgically Resected, High-Risk Patients With Ampullary Adenocarcinoma: A Population-Based Analysis
(S016) The Impact of Stereotactic Body Radiation Therapy on Overall Survival in Patients With Locally Advanced Pancreatic Cancer

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
Opportunities to further reduce relapses include pembrolizumab-based combination therapy and evaluating the agent’s contribution before and after surgery.
For patients with locally advanced head and neck cancers, the current standard of care for curative therapy has a cure rate of less than 50%.
According to Maurie Markman, MD, patient-reported outcomes pertain to more relevant questions surrounding the impact of therapy for patients.
Future findings from a translational analysis of the OVATION-2 trial may corroborate prior clinical data with IMNN-001 in advanced ovarian cancer.
Related Content

29 A Real-World Exploratory Analysis to Identify Disparities in Breast Cancer Tumor Biopsy Practice at Community Oncology Clinics in the United States

29 A Real-World Exploratory Analysis to Identify Disparities in Breast Cancer Tumor Biopsy Practice at Community Oncology Clinics in the United States

Sibel Blau;Ajithkumar Puthillath, MD;Nik Seifter;Gene Felber;Julie Katz;Aaron Peevyhouse;Heather Neuhalfen;George Dranitsaris
June 17th 2025
Article

An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.

CAR T and Transplantation Advances Across Hematologic Cancers at ASCO 2025

Rahul Banerjee, MD, FACP;Taha Al-Juhaishi, MD;Muhammad Salman Faisal, MD
June 9th 2025
Podcast

An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.


Elranatamab Triplet Induces Early and Deep Responses in Newly Diagnosed MM

Elranatamab Triplet Induces Early and Deep Responses in Newly Diagnosed MM

Ariana Pelosci
June 16th 2025
Article

The MagnetisMM-6 trial showed that elranatamab plus daratumumab and lenalidomide yielded an ORR of 97.3% in transplant-ineligible multiple myeloma.


Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.

Spotlighting Key Upcoming Presentations Across Oncology at ASCO 2025

Rachel N. Grisham, MD;MinhTri Nguyen, MD;Eric Singhi, MD;Douglas Adkins, MD;Benjamin Garmezy, MD
May 26th 2025
Podcast

Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.


Low rates of early relapse in both arms of the phase 3 IsKia trial support the efficacy of carfilzomib in this newly diagnosed multiple myeloma setting.

Isatuximab Combination Significantly Sustains MRD Negativity in NDMM

Russ Conroy
June 16th 2025
Article

Low rates of early relapse in both arms of the phase 3 IsKia trial support the efficacy of carfilzomib in this newly diagnosed multiple myeloma setting.


Data from ASCERTAIN-V may support venetoclax plus decitabine/cedazuridine as a new standard of care in those with AML ineligible to receive chemotherapy.

Oral Venetoclax Combo Elicits Responses, Survival in Newly Diagnosed AML

Gina Mauro
June 15th 2025
Article

Data from ASCERTAIN-V may support venetoclax plus decitabine/cedazuridine as a new standard of care in those with AML ineligible to receive chemotherapy.

Related Content

29 A Real-World Exploratory Analysis to Identify Disparities in Breast Cancer Tumor Biopsy Practice at Community Oncology Clinics in the United States

29 A Real-World Exploratory Analysis to Identify Disparities in Breast Cancer Tumor Biopsy Practice at Community Oncology Clinics in the United States

Sibel Blau;Ajithkumar Puthillath, MD;Nik Seifter;Gene Felber;Julie Katz;Aaron Peevyhouse;Heather Neuhalfen;George Dranitsaris
June 17th 2025
Article

An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.

CAR T and Transplantation Advances Across Hematologic Cancers at ASCO 2025

Rahul Banerjee, MD, FACP;Taha Al-Juhaishi, MD;Muhammad Salman Faisal, MD
June 9th 2025
Podcast

An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.


Elranatamab Triplet Induces Early and Deep Responses in Newly Diagnosed MM

Elranatamab Triplet Induces Early and Deep Responses in Newly Diagnosed MM

Ariana Pelosci
June 16th 2025
Article

The MagnetisMM-6 trial showed that elranatamab plus daratumumab and lenalidomide yielded an ORR of 97.3% in transplant-ineligible multiple myeloma.


Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.

Spotlighting Key Upcoming Presentations Across Oncology at ASCO 2025

Rachel N. Grisham, MD;MinhTri Nguyen, MD;Eric Singhi, MD;Douglas Adkins, MD;Benjamin Garmezy, MD
May 26th 2025
Podcast

Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.


Low rates of early relapse in both arms of the phase 3 IsKia trial support the efficacy of carfilzomib in this newly diagnosed multiple myeloma setting.

Isatuximab Combination Significantly Sustains MRD Negativity in NDMM

Russ Conroy
June 16th 2025
Article

Low rates of early relapse in both arms of the phase 3 IsKia trial support the efficacy of carfilzomib in this newly diagnosed multiple myeloma setting.


Data from ASCERTAIN-V may support venetoclax plus decitabine/cedazuridine as a new standard of care in those with AML ineligible to receive chemotherapy.

Oral Venetoclax Combo Elicits Responses, Survival in Newly Diagnosed AML

Gina Mauro
June 15th 2025
Article

Data from ASCERTAIN-V may support venetoclax plus decitabine/cedazuridine as a new standard of care in those with AML ineligible to receive chemotherapy.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.